## Appropriate use of medicines in care of the elderly

Factors underlying inappropriateness, and impact of the clinical pharmacist

Anne Spinewine PhD, MSc Clinical Pharmacy Société Belge des Sciences Pharmaceutiques Spa, 11.10.2007



Optimising the use of medicines hospitals is central to the quality of patient care in hospitals.

A spoonful of sugar, NHS 2001

- Medicines can save lives. But they can harm too.
- Landmark study on adverse drug events (ADEs): (Bates, 1995 and 1997)
  - 6.5 ADEs / 100 hospital admissions
  - 12% life threatening, 30% serious
  - 28-42% are preventable
    - Annual cost for a 700-bed teaching hospital: \$2.8 million



Optimising the use of medicines hospitals is central to the quality of patient care in hospitals.

A spoonful of sugar, NHS 2001

- How to prevent « preventable ADEs »?
  - Prescription and administration must be optimised
  - Build safety into the systems of care (≠ blame individuals)
  - « 2 of the most interesting changes (...) are computerised-physician order entry, and redefinition of the role of pharmacists to make them onsite members of the unit patient care team. » (Bates, 1995)

- <u>Clinical pharmacy pharmaceutical care</u>
  - A clinical pharmacist should aim to maximise therapeutic <u>effect</u>, to minimise <u>risk</u>, to minimise <u>cost</u> and to respect <u>patient</u> choice. (Barber, 1996)

Patient-centered services

« Ward pharmacy » « Pharmaceutical care »





- <u>Clinical pharmacy : International experience</u>
  - 35-year experience in US/Canada/UK
    - Pharmacists attend rounds in 80% of large US hospitals (Pedersen, 2005)
    - 94% of Canadian hospitals provide clinical pharmacy services (Bussières, 2001)
      - 40% of pharmacists' time devoted to clinical activities
    - 60% of hospital pharmacists in the UK provide patient counselling (Cotter, 1994)
  - Evidence of positive impact on various outcomes (Spinewine, 2003)
    - Clinical:  $\downarrow$  ADEs,  $\downarrow$  morbidity,  $\downarrow$  mortality
    - Economic:  $\downarrow$  direct and indirect costs
    - Humanistic: ↑ satisfaction



- <u>Clinical pharmacy: Belgian experience in 2000</u>
  - Patient-centered services: (almost) inexistant
    - (Spinewine 2003, Willems 2005)

- Hospital pharmacists' activities:
  - 70% distribution, 16% manufacturing or compounding
  - 10% other activities
- When regular ward visits:
  - 1 hour/day
  - Stock control, collecting prescriptions, solving drug-related problems



• <u>Clinical pharmacy: Belgian experience</u>

- BUT...
  - Opportunities for development:
    - National willingness to improve quality and safety,  $\downarrow$  nb of doctors
  - Barriers to overcome:
  - Resources, acceptation, training
    (Spinewine and Dhillon, 2002)

Main research hypothesis:

Pharmaceutical care provided to patients at high risk of drug-related problems improves the quality of use of medicines

### (1) Target: frail elderly patients *High risk of drug-related problems*



#### Risk factors

- Comorbidities +++
- PK/PD changes
- Physical/cognitive impairment

#### Problems with drugs

- Polymedication
- Inappropriate prescribing
- Poor compliance

#### <u>Consequences</u>

- Clinical
- $\uparrow$  ADEs, morbidity, mortality
- Economic
- ↑ costs
- Humanistic
- $\downarrow$  quality-of-life

#### Examples:

- 50% of admissions to hospital that are secondary to an ADE are preventable
- 50% of elderly patients do not take their drugs as intended
- 1 € spent on drugs → 1.33 € spent to treat drug-related problems (Bootman, 1997)



### (2) Rigorous evaluation of impact

Structured and logical approach



- Assess the baseline level of appropriateness of use of medicines → needs identification
- 2. Design the intervention (must address the needs)
- 3. Implement the intervention / service
- 4. Evaluate impact on quality
  - 1. Robust study design
  - 2. Validated process and outcome measures

### (2) Rigorous evaluation of impact



Structured and logical approach

 Assess the baseline level of appropriateness of use of medicines → needs identification

#### Qualitative research in health care

#### QUALITATIVE

#### <u>Approach</u>

often exploratory work: "how" and "why" hypothesis generating

Why do inappropriate use of medicines occur?

*↔ quantitative* 

↔ how many?↔ testing

What is the % of inappropriate prescriptions?

What is the impact of clinical pharmacists on this %?

#### Qualitative research in health care

#### QUALITATIVE

#### <u>Approach</u>

often exploratory work: "how" and "why" hypothesis generating

#### **Methods**

interviews, observation, documents

#### <u>Sample</u>

small and purposive

*↔ quantitative* 

↔ how many?↔ testing

 $\leftrightarrow$  survey, RCT

 $\leftrightarrow$  large, random

## I. Qualitative study - objective



- 1a. To explore the <u>perceptions</u> of HCPs on the appropriateness of use of medicines for elderly inpatients
- 1b. To identify the <u>processes</u> leading to (in)appropriate use of medicines

with regard to prescribing, counselling, and transfer of information to the general practitioner

Appropriateness of use of medicines in elderly inpatients: qualitative study Spinewine A, Swine C, Dhillon S, Dean Franklin B, Tulkens PM, Wilmotte L, Lorant V. *British Medical Journal* 2005;331:935-9.

## I. Qualitative study - design

#### 1. DATA COLLECTION





#### 2. DATA ANALYSIS

Read transcripts → themes → coding → ... Inductive, multidisciplinary approach Software support: QSR N-Vivo

## I. Qualitative study - results

#### Perceived appropriateness

- Inappropriate prescribing does occur
- Patient counselling is insufficient
- Information given to the general practitioner upon discharge, and relating to medicines, is insufficient

 $\rightarrow$  Why does this occur?



## I. Qualitative study - results

Why does inappropriate prescribing occur?

1. Prescribing is not tailored to ELDERLY patients

*« Doctors haven't necessarily been trained in geriatrics. They will start with 10mg of morphine every 4 hours. That's too much. »* 

#### 2. Searching for medicines information: takes too long

« I don't really know drug interactions very well. And to always go and look in the compendium is a bit difficult in terms of time. »

#### 3. Paternalism – patients are thought to be conservative

« Patients are attached to their medicines. It is difficult to go against that. »

## I. Qualitative study - discussion

- Underlying factors  $\rightarrow$  approaches for improvement

 Support by a clinical pharmacist could tackle several of the underlying factors







Hospital stay

Plan Design Figure 1: Pharmaceutical care process used in the study





Abbreviations: DRP: drug-related problem; EBM: evidence-based medicine; HCP: health car professional; SPC: summary of product characteristics. Grey dotted boxes represent persons with whom the clinical pharmacist collaborated.



# III. Implementation and evaluation

#### **Objectives**

3a. To evaluate the feasibility to provide pharmaceutical care

3b. To evaluate the impact on the quality of use of medicines

#### Acute geriatric unit, Mont-Godinne teaching hospital, 7 months

Implementation of ward-based clinical pharmacy services in Belgium – Description of the impact on a geriatric unit.

Spinewine A, Dhillon S, Mallet L, Tulkens PM, Wilmotte L, Swine C.

Annals of Pharmacotherapy 2006;40:720-8.

Impact of a collaborative approach on the quality of prescribing for geriatric inpatients. A randomized controlled trial.

Spinewine A, Swine C, Dhillon S, Lambert P, Nachega J, Wilmotte L, Tulkens PM.

Journal of the American Geriatrics Society 2007; 55:658-665

#### How to evaluate the impact of pharmaceutical care?

#### <u>Descriptive</u> approach

 Description of interventions made by the clinical pharmacist to optimise the use of medicines

#### <u>Comparative</u> approach

- Comparison with a control group
- Measures of impact

## III. Evaluation – descriptive study

- 101 patients
- 82.2 ± 6.9 years
- $7.8 \pm 3.5$  prescribed drugs

Mean nb of interventions per patient Initiated by:

- The pharmacist:  $8.9 \pm 6.0$
- Another professional: 1.6 ± 1.6

#### Most frequent recommendations:

- Discontinue medicine 24.5%
- Add a new drug 18.6%
- Change dose 12.5%
- Educate HCP 10.0%
- Switch to other drug 8.9%

#### **Acceptation**

- Fully accepted 88%
- Partially accepted 7%
- Rejected 5%

## **III**. Evaluation – descriptive study

#### Clinical significance (n=700) :

- Moderate
- Major
- Minor

28.6% 2.6%

68.3%



5 « moderate » interventions per patient2 « major » interventions per patient

#### How to evaluate the impact of pharmaceutical care?

#### <u>Descriptive</u> approach

 Description of interventions made by the clinical pharmacist to optimise the use of medicines

#### <u>Comparative</u> approach

- Comparison with a control group
- Measures of impact
  - « Process » measures : quality measures
    - Appropriateness of prescribing
  - « Outcome » measures
    - Clinical: ADE, length of stay, mortality, readmission
    - Economic: cost of drugs, cost of hospital stay,...
    - Humanistic: quality-of-life, satisfaction



## III. Evaluation – RCT – design

#### <u>Descriptive</u> approach

 Description of interventions made by the clinical pharmacist to optimise the use of medicines

#### <u>Comparative</u> approach

- Comparison with a control group
- Measures of impact



- « Process » measures : quality measures
  - Appropriateness of prescribing (on admission and at discharge)
- « Outcome » measures
  - Clinical: ADE, length of stay, mortality, readmission
  - Economic: cost of drugs, cost of hospital stay,...
  - Humanistic: quality-of-life, satisfaction

#### 1. Medication Appropriateness Index (MAI)

% of patients with >1 inappropriate rating?

- 1. Valid indication?
- 2. Appropriate choice?
- 3. Correct dose?
- 4. Modalities of treatment correct?
- 5. Modalities of treatment practical?
- 6. Clin. significant drug-drug interactions?
- 7. Clin. significant drug-disease interactions?
- 8. Duplication?
- 9. Appropriate duration?
- 10. Cost?

1. Medication Appropriateness Index (MAI)

% of patients with >1 inappropriate rating?

2. Drug-to-avoid criteria (Beers) e.g. long-acting BZD, amitriptyline, dipyridamole

% of patients taking ≥1 Beers' drug? % of patients with previous fall and taking a BZD?

Spinewine et al., Lancet 2007;370:173-84

1. Medication Appropriateness Index (MAI)

% of patients with >1 inappropriate rating?

#### 2. Drug-to-avoid criteria (Beers)

% of patients taking ≥1 Beers' drug? % of patient with previous fall and taking a BZD?

3. Underuse ACOVE criteria

e.g. patient with myocardial infarction and not on aspirin e.g. patient with osteoporosis and not treated

% of patients with ≥1 underuse event ?

Spinewine et al., Lancet 2007;370:173-84

1. Medication Appropriateness Index (MAI)

% of patients with  $\geq$ 1 inappropriate rating?

#### 2. Drug-to-avoid criteria (Beers)

% of patients taking ≥1 Beers' drug? % of patient with previous fall and taking a BZD?

#### 3. Underuse ACOVE criteria

% of patients with  $\geq$ 1 underuse event ?



**III.** Evaluation – RCT – results ON ADMISSION 1. Medication Appropriateness Index (MAI) % of patients with  $\geq 1$  inappropriate rating? 2. Drug-to-avoid criteria (Beers) % of patients taking >1 Beers' drug? % of patient with previous fall and taking a BZD? 3. Underuse ACOVE criteria % of patients with ≥1 underuse event ?





## **III**. Evaluation – RCT – results

#### **IMPROVEMENTS FROM ADMISSION TO DISCHARGE**



## **III**. Evaluation – RCT – results

#### **IMPROVEMENTS FROM ADMISSION TO DISCHARGE**



## **III**. Evaluation – RCT – results

#### • <u>Descriptive</u> study

 Description of interventions made by the clinical pharmacist to optimise the use of medicines

#### <u>Comparative</u> study

<mark>2</mark>°

- Comparison with a control group
- Measures of impact
  - « Process » measures
    - Appropriateness of prescribing maintenance of improvements after discharge
  - « Outcome » measures
    - Clinical: ADE, length of stay, mortality, eadmission
    - Economic: cost of drugs, cost of hospital stay,...
    - Humanistic: quality-of-life, satisfaction

## III. Evaluation – discussion

- Moderate/high levels of inappropriate prescribing at baseline
- Impact of pharmaceutical care:
  - At the prescriber level:
    - Improvement in the quality of medicines use
    - Persistance after discharge
    - Possible educational bias

At the patient level:

- Increased satisfaction with information received on medicines
- Impact on clinical outcomes? Sample too small
- Relative impact compared to other approaches for optimisation?



• Comparison with computerised prescribing

## Discussion – What have we learned?



- Need to optimise use of medicines in the elderly
- Several categories of causal factors need to be addressed
- Providing pharmaceutical care
  - is feasible and well accepted
  - improves the quality of use of medicines
  - cannot be replaced by a computerised prescr. system



- New European data on inappropriate prescribing
- 1st time qualitative approach taken
- MAI, reliability: new findings
- New and robust data on impact in acute geriatrics
- Of interest for implementation in other European countries

## Perspectives



#### <u>Clinical pharmacy in Belgium – What's next?</u>

- 1. Generalisabity of our results
  - to other hospitals, units, pharmacists
  - ongoing pilot studies; new positions created (Ampe, 2006)
  - Perspective: use similar tools to evaluate impact; design a multicenter study



## Perspectives



#### Clinical pharmacy in Belgium – What's next?

- 1. Generalisabity of our results
  - to other hospitals, units, pharmacists
  - ongoing pilot studies; new positions created (Ampe, 2006)
  - Perspective: use similar tools to evaluate impact; design a multicenter study
- 2. Economic impact ???
  - Impact on direct v. indirect costs
- Litterature: mean benefit:cost ratio = 4.68:1 (Schumock, 2003)
- Belgian data are essential for successful expansion
- Perspective: evaluate impact in the context of the new prospective budgeting system

## Perspectives

#### Final thoughts for the future

 The needs differ between units and patients – Always adapt the service to the needs, and prioritise.

#### • Essential components of success: clinical pharmacists must have:

- Direct contacts with patients and HCPs
- Access to patient records
- A structured approach to treatment review and optimisation
- Adequate knowledge and skills → current efforts to develop specific educational programs should be pursued and extended.
- Articulate pharmaceutical care services with decentralised clinical pharmacy services (eg guideline development, computerised prescribing)



## Collaborators

- UCL
  - Acute geriatric unit, Mont-Godinne Hospital
  - Vincent Lorant, SESA
  - CUMG (JM Feron, D Paulus,...)
  - Statistics department, LLN
- External collaborators
  - UK: S Dhillon, B Dean, N Barber (School of Pharmacy, London)
  - Canada: Louise Mallet
  - FNRS